Key Findings From Recent Trials

Basic Chloroquine Information

• INN (International Nonproprietary Name): Chloroquine.
• Brand Names Available In Canada (English): Not specified.
• ATC Code: P01BA01 — Chloroquine (antimalarial agent), classified under Antimalarials (P01B) and Antiprotozoals (P01).
• Forms & Dosages: Tablets 100 mg, 150 mg, 250 mg, 500 mg; Syrup/Solution 50 mg/5 ml (pediatric); Injectable forms 150 mg base/ml (limited use).
• Manufacturers In Canada (English): Not specified.
• Registration Status In Canada (English): Not specified.
• OTC / Rx Classification: Prescription Only (Rx) in nearly all countries.

Worried whether chloroquine still has a place after the COVID era and recent safety advisories?

High-quality randomized controlled trials and meta-analyses from 2022 to 2025 consistently show no meaningful clinical benefit of chloroquine or hydroxychloroquine for COVID-19.

Major international systematic reviews emphasised safety risks, particularly cardiac arrhythmias linked to QT prolongation.

Canadian post-market surveillance and Health Canada advisories between 2022 and 2024 flagged reports of QT prolongation and advised caution in off-label prescribing.

Malaria surveillance continues to report declining clinical use in many regions due to Plasmodium falciparum resistance, with artemisinin-based combination therapies remaining first-line under WHO guidance.

Major 2022–2025 Canadian & Global Studies

Clinicians and patients asked in 2022–2025 whether evidence ever supported COVID-19 use; the best-quality randomized trials did not.

Meta-analyses synthesizing RCT data reaffirmed lack of mortality or morbidity advantage for chloroquine in COVID-19 treatment.

Health Canada pharmacovigilance summaries recorded safety signals that influenced prescribing behaviour and professional advisories.

Malaria-focused surveillance data emphasise regional resistance patterns and the shift to ACTs where chloroquine resistance is common.

Main Outcomes

No consistent mortality or morbidity benefit for COVID-19 emerged from high-quality trials.

Chloroquine retains usefulness as an antimalarial in areas where parasite susceptibility remains documented.

At rheumatologic maintenance doses, chloroquine can be effective for SLE and RA when monitored appropriately.

Safety Observations

Post-market reports and trial safety data consistently highlighted cardiotoxicity risks, including QT prolongation and arrhythmias.

Retinopathy remains a rare but serious complication with long-term or high-dose exposure.

Hypersensitivity reactions and seizure risk were noted as important safety considerations in reports to regulators.

Clinical Mechanism Of Action

Curious how chloroquine kills parasites and why it affects other organs like the heart and eye?

Chloroquine is an antimalarial that concentrates in parasite-containing compartments and disrupts the parasite’s detoxification of haem.

It also has mild immunomodulatory effects that explain some chronic rheumatology use.

Layman’s Explanation

The drug builds up inside acidic compartments where malaria parasites digest blood products.

That build-up raises the acidity and interferes with the parasite’s ability to neutralize toxic haem, causing parasite death.

At lower, longer-term doses the drug dampens certain immune signals, which helps in conditions such as systemic lupus erythematosus and rheumatoid arthritis.

Scientific Breakdown

Chloroquine is a weak base that accumulates in lysosomes and food vacuoles, increasing pH and disrupting parasite digestion.

The main antiplasmodial action is inhibition of haem polymerization into hemozoin, leaving toxic haem to damage parasite membranes.

Antiplasmodial Effects

By blocking conversion of haem to hemozoin, chloroquine causes haem-mediated toxicity within the parasite’s digestive vacuole.

This mechanism explains its potency against chloroquine-sensitive strains of Plasmodium species.

Immunomodulatory & Off-Target Effects

Chloroquine modulates Toll-like receptor signalling and antigen presentation, which reduces inflammatory signalling in autoimmune disease.

Those same off-target effects, plus direct ion-channel impacts, help explain cardiac electrophysiology effects such as QT prolongation.

ATC Classification: P01BA01 (antimalarial/antiprotozoal).

Scope Of Approved & Off-Label Use

Wondering when chloroquine is actually an approved therapy in clinical practice and when it was used off-label?

In most jurisdictions chloroquine is a prescription-only medicine used primarily for malaria and certain rheumatologic conditions.

Health Canada Approvals (DIN-Based)

In Canada a marketed product must have a Drug Identification Number (DIN) and chloroquine is prescription-only.

Primary approved indications align with international uses: acute malaria where susceptibility exists, long-term rheumatologic therapy for SLE/RA, and certain protozoal infections like amebiasis.

Packaging and strengths internationally include tablets from 100 mg to 500 mg, pediatric syrups and injectables, but Canadian marketing trends toward tablet forms dispensed by pharmacies.

Notable Off-Label Trends In Canadian Practice

Off-label prescribing rose sharply during the COVID-19 period but was curtailed after high‑quality trial evidence and regulatory advisories.

Rheumatologists often favour hydroxychloroquine for tolerability, with chloroquine used where hydroxychloroquine intolerance or supply issues exist.

Long-term use of either drug requires ophthalmologic surveillance to manage retinal risk.

Dosage Strategy

Are you unsure how dosing differs for malaria, children and chronic rheumatologic use?

Follow weight-based guidance for children and adhere to product monographs for adults to reduce toxicity risk.

General Dosing Per Health Canada Monographs

For acute malaria adult dosing the standard base regimen is 600 mg base initially, then 300 mg base at 6, 24 and 48 hours for a total of 1.5 g base.

Tablet strengths commonly available worldwide include 100 mg, 150 mg, 250 mg and 500 mg, and a pediatric syrup is typically 50 mg/5 mL for weight-based dosing.

Condition-Specific Dosing Adjustments

Pediatric acute malaria dosing is 10 mg/kg base initially, then 5 mg/kg base at 6, 24 and 48 hours, with weight-based calculations throughout.

Rheumatology maintenance doses are generally 250–500 mg daily, with dose calculations guided by ideal body weight to minimise retinopathy risk.

In elderly patients and those with renal or hepatic impairment dose reduction and extended monitoring are recommended because of accumulation risk and increased cardiotoxicity and seizure risk.

Overdose is life-threatening; seek emergency care immediately for suspected ingestion with symptoms such as arrhythmia, seizures or respiratory compromise.

Safety Protocols

Worried about vision loss, heart rhythm problems or troublesome side effects while taking chloroquine?

Risk assessment before starting therapy and scheduled monitoring during treatment reduce the chance of serious harm.

Contraindications (Canadian Advisories)

Absolute contraindications include known hypersensitivity to chloroquine or related compounds, preexisting retinal or visual field changes, and a history of epilepsy.

Relative contraindications requiring close monitoring include liver or renal impairment, psoriasis, porphyria, myasthenia gravis, alcoholism, and concomitant use of QT‑prolonging agents.

Adverse Effects (Post‑Market Reports)

Common mild adverse effects are nausea, headache, pruritus (more common in some African populations) and loss of appetite.

Moderate effects reported include blurred vision, rash, dyspepsia and mood changes.

Serious long-term risks include irreversible retinopathy and cardiomyopathy, with ECG monitoring advised for those at cardiac risk or taking QT‑prolonging drugs.

Baseline ophthalmologic examination and periodic screening are recommended for patients on long-term therapy.

Interaction Mapping

Want to know which foods and medicines you must avoid while on chloroquine?

Counselling on drug interactions and simple food guidance helps prevent avoidable adverse outcomes.

Food Interactions Common In Canadian Diet

Chloroquine may be taken with food to reduce gastrointestinal upset, and high‑fat meals only modestly alter absorption and are not clinically prohibitive.

Advise patients to limit alcohol while on treatment because of additive hepatic and central nervous system effects.

If antacids are used, separate dosing may be sensible depending on the antacid formulation to avoid any absorption issues.

Drug Combinations Flagged By Health Canada

Major interaction concerns include combination with other QT‑prolonging agents such as macrolide antibiotics, certain antipsychotics and some antiarrhythmics.

Agents that lower the seizure threshold (for example bupropion and tramadol) can increase risk when combined with chloroquine.

Drugs altering CYP pathways may change chloroquine plasma levels, and concurrent hydroxychloroquine increases cumulative cardiotoxic risk.

When combining with QT‑prolonging drugs, obtain an ECG and check electrolytes, and review provincial formularies and patient medication lists including OTC and herbal products.

Patient Experience Analysis

What do Canadian patients actually ask about chloroquine at the pharmacy counter?

Most interactions concern prescription queries, side‑effect worries and historical COVID‑era questions.

Canadian Survey Data

Provincial pharmacovigilance summaries and pharmacy records show common queries relate to GI upset, itching and vision changes, and to past requests during the COVID period.

Access is influenced by provincial drug plans such as Ontario Drug Benefit, BC PharmaCare and RAMQ which may require prior authorisation or a physician letter for coverage.

Forum & Community Pharmacy Trends

Community pharmacists report occasional stock variability related to generic supply chains and frequent counselling about retinal monitoring for chronic users.

Pharmacists routinely caution against cross‑border online purchases without a DIN because of product and regulatory risks.

Online forums still reflect confusion from the pandemic era, so pharmacists and provincial resources remain important trusted points of information.

Distribution & Pricing Landscape

Looking for where to get chloroquine in Canada and how coverage or price compares to the US?

Availability depends on manufacturers, imports and provincial formularies rather than a single national supplier list.

National Pharmacy Chains

Major chains such as Shoppers, Rexall, Jean Coutu and London Drugs dispense chloroquine when prescribed, subject to supply and provincial inventory management.

Pharmacies may source international brands like Nivaquine or Aralen, or generic equivalents depending on importation and manufacturer licensing.

Online Pharmacy Availability & Provincial Restrictions

Verified Canadian online pharmacies require a DIN and prescription for dispensing and comply with bilingual labelling and counselling obligations.

Provincial drug plans determine coverage and many do not list chloroquine routinely given its limited current indications; prior authorisation may be required for reimbursement.

In our online pharmacy, chloroquine is available without a prescription, with discreet delivery to Canada (English) in 5-14 days.

Cross-Border US Comparisons

US brands such as Aralen differ in packaging and pricing, and cross‑border purchasing risks include customs issues, lack of a DIN and no provincial reimbursement.

Patients should verify the product’s NOC/DIN status and provincial coverage rules before attempting importation.

Alternative Options

Wondering what alternatives exist if chloroquine is unsuitable because of resistance, toxicity or formulary limits?

Choice of therapy depends on the indication, parasite resistance patterns and patient comorbidities.

Comparison Of DIN-Approved Alternatives

Hydroxychloroquine is a common alternative used in rheumatology and often preferred for perceived safety and tolerability.

Where P. falciparum resistance to chloroquine is prevalent, artemisinin-based combination therapies are recommended as first-line treatment.

Other antimalarial options include mefloquine for some traveller contexts and primaquine for radical cure of P. vivax, the latter requiring G6PD testing.

Pros And Cons Checklist

• Pros: Low cost when effective, time-tested antimalarial for sensitive strains and longstanding inclusion in essential medicines lists.
• Cons: Widespread resistance in many regions, cardiac and retinal toxicity with higher or prolonged exposure, monitoring burden and Rx-only status.

Regulatory Status

Need to know what regulatory steps a product must clear to be sold in Canada or how post‑market safety is handled?

Regulatory oversight ensures product quality and ongoing safety monitoring once a product is on the market.

Health Canada Approval Process

Chloroquine requires either a New Drug Submission or an equivalent regulatory pathway to gain a DIN for marketed Canadian formulations.

Canada Vigilance collecte adverse event reports and Health Canada issues advisories when safety signals, such as QT prolongation or retinopathy, emerge.

Prescribers must follow labelled indications and monitoring recommendations, and off‑label use remains clinician discretion under professional oversight.

DIN And Bilingual Labelling Rules

All prescription drugs marketed in Canada must bear a DIN and comply with bilingual (English/French) labelling where applicable.

Provincial drug plans and pharmacies rely on DINs for reimbursement, stock control and verifying manufacturer licensing and GMP certification.

Consolidated FAQ

Got quick questions about access, coverage or long-term risks? Below are clear answers.

• Q1: Is chloroquine available over the counter in Canada?

  A1: No — chloroquine is prescription-only (Rx) and requires a DINed product and pharmacist dispensing.

• Q2: Do provincial drug plans cover chloroquine?

  A2: Coverage varies by province and indication, and prior authorisation may be required by ODB, BC PharmaCare and RAMQ for listed uses.

• Q3: How is long‑term retinal risk managed?

  A3: Baseline ophthalmologic exam before starting long-term therapy and periodic screening thereafter based on dose, duration and patient risk factors.

• Q4: Can I import chloroquine from the US for personal use?

  A4: Cross-border importation carries risks including lack of a DIN, customs issues and no provincial reimbursement; check Health Canada guidance and your provincial plan first.

Visual Guide

Want simple, shareable visuals to help patients follow dosing and monitoring steps?

Designers should create four clear infographics with bilingual labels and accessible formats.

Include a dosage flowchart for adult and pediatric acute malaria regimens using tablet strengths 100–500 mg and syrup 50 mg/5 mL.

Provide a provincial coverage map colour-coded for ODB, BC PharmaCare and RAMQ listed versus non‑listed status.

Show purchase channels with icons for community pharmacy chains and verified online pharmacies, and a monitoring checklist with baseline ECG and ophthalmology checkpoints.

Accessibility notes: use high-contrast colours, alt text, printable size and quick safety badges such as “Prescription Only — Seek Emergency Care For Overdose” and “Potential QT Risk — Inform Prescriber Of All Meds.”

Storage & Transport

Not sure how to store tablets or what to do if a package is exposed to heat during shipping?

Proper storage and handling reduce the risk of degradation or accidental ingestion, especially in homes with children.

Canadian Household Guidelines

Store chloroquine at controlled room temperature between 15–25°C, protected from light and moisture.

Keep the product in its original container with DIN and expiry information and keep it out of reach of children because pediatric syrup poses a particular accidental ingestion risk.

Consider pharmacy-labelled dose organizers or blister packs to reduce dosing errors in households with multiple prescriptions.

Cold-Chain Storage Where Applicable

Injectable chloroquine forms may have manufacturer-specific storage instructions; verify the monograph for those products.

Pharmacies should follow Good Distribution Practices for temperature control during transport and document any temperature-sensitive courier runs.

Report suspected temperature excursions to the dispensing pharmacist and manufacturer for instructions on product integrity.

Guidelines For Proper Use

Looking for a practical checklist pharmacists and patients can follow when starting chloroquine?

Clear stepwise counselling and adherence to provincial guidance keep therapy safe and effective.

Advice From Canadian Pharmacists

Confirm the indication, verify the DIN and dose, and counsel on whether to take the medication with food to reduce GI upset.

Warn about QT risks and review the full medication list for interacting agents including OTC and herbal products.

Advise baseline ophthalmology and periodic screening for long-term therapy, instruct on emergency actions for overdose, and discourage non‑DIN imports.

Document counselling and check for any prior authorisation requirements with provincial drug benefit programs.

Provincial Health Authority Guidance

Follow local formularies such as Ontario Drug Benefit, BC PharmaCare and RAMQ for listing and monitoring rules.

For travel-related malaria prevention or treatment, align prescribing with WHO and provincial public health guidance on regional parasite resistance, using ACTs where resistance to chloroquine is documented.

Delivery Across Canada (English)

Closing Notes For Patients And Clinicians

Many patients ask whether chloroquine remains on formularies and if hydroxychloroquine is safer.

Hydroxychloroquine is commonly used in rheumatology for perceived better tolerability, but both drugs share retinal risk and cardiac considerations.

Decisions about using chloroquine should be guided by indication, regional parasite resistance, patient comorbidities and provincial coverage rules.

If you are a long-term user, keep scheduled ophthalmology appointments and inform your prescriber of any new medications that could prolong the QT interval.

For travellers, consult a travel clinic or public health unit to align prevention with current WHO and provincial guidance, and consider ACTs where chloroquine resistance is present.

If you have concerns about side effects or drug interactions, speak to your pharmacist and prescriber and bring a complete medication list to every appointment.